Thompson Street Capital Partners Expands Biologics Portfolio with Isto Biologics Merger

Thompson Street Capital Partners (TSCP) announces merger with Advanced Biologics/Biologica Technologies to enhance bone graft portfolio and accelerate patient healing.

St. Louis, MO - Thompson Street Capital Partners (TSCP), a leading private equity firm based in St. Louis, has announced the merger of Isto Biologics, a portfolio company of TSCP and a global leader in regenerative and autologous therapies, with Advanced Biologics (Biologica Technologies). This strategic merger will further expand Isto Biologics' growing portfolio of bone grafts and seamlessly integrate Advanced Biologics' proprietary products alongside Influx™, Isto's esteemed line of cortical fiber allografts.

"We are excited to welcome the entire Advanced Biologics team to Isto Biologics," said Donald Brown, CEO of Isto Biologics. "This merger brings together the best of both companies' expertise and a shared commitment to helping patients heal faster."

The partnership between Isto Biologics and Advanced Biologics began in 2020, and since then, they have maintained a commercial partnership. This collaboration was driven by the development of Isto's Integrative Bone Matrix, SPARCTM, a novel inductive bone matrix that utilizes Advanced Biologics' proprietary tissue processing method used in their flagship product OsseoGEN. SPARCTM is known for its increased levels of osteoinductive, chemotactic, angiogenic, and proliferative growth factors.

The integration of Advanced Biologics' product commercialization initiatives into Isto's allograft portfolio represents a unique opportunity to accelerate patient healing and provide a broader range of products to both customer bases.

"With this merger, our combined team now brings greater clinical expertise and deeper customer support to provide our surgeon champions with the best products available on the market," said Amit Govil, President of Advanced Biologics.

Over the past four years, Isto Biologics and Advanced Biologics have collaborated extensively, leading to impressive results. "Investing in Advanced Biologics and embarking on this strategic combination amplifies both Isto's and Advanced Biologics' comprehensive biologics portfolios, paving a path forward for continued growth and patient healing," said Harry Holiday, Chairman of the Board at Isto Biologics and Managing Director at Thompson Street Capital Partners.

Thompson Street Capital Partners is a St. Louis-based private equity firm that focuses on investing in founder-led middle-market businesses. With over 200 acquisitions in various sectors, including Life Sciences & Healthcare Services, Software & Technology, and Business Services & Consumer Products, TSCP has managed more than $4.5 billion since its inception in 2000. The firm partners with management teams to accelerate growth and increase value through organic expansion and strategic acquisitions.

Isto Biologics is a leading biologics and cellular therapy company specializing in orthopedics. The company is dedicated to Helping Patients Heal Faster™ through innovative solutions for bone regeneration and cell-based therapies. Isto Biologics offers a range of market-leading products, including the Magellan® Autologous Platelet Separator, InQu® Bone Graft Extender & Substitute, and the Influx™ product family.

Advanced Biologics/Biologica Technologies is a renowned biologics company that has received multiple Orthopedics This Week - New Technology Awards for its innovative and clinically relevant biologic solutions. In 2015, Advanced Biologics established Biologica Technologies as a separate entity to handle sales, marketing, and clinical research. The company's core proprietary technology allows access to intracellular growth factors (GFs) found within allograft tissue. Their products, such as ProteiOS® growth factor and OsseoGEN® cellular bone matrix, utilize this technology and possess the highest amount of GFs in their respective biologic categories. Headquartered in Carlsbad, CA, Advanced Biologics/Biologica Technologies is a privately-held company.

In conclusion, the merger between Isto Biologics and Advanced Biologics/Biologica Technologies represents a significant step forward in the biologics industry. With their combined expertise and commitment to patient healing, these companies are well-positioned to continue their growth and deliver innovative solutions for bone regeneration and cell-based therapies.